People buy a lot on the gray market. What does that mean?
“Gray market” is where most peptides are actually sold — labeled “for research only, not for human use.” It isn’t a black market and it isn’t a pharmacy. It’s the in-between, and the safest way to understand it is to keep four words apart.
The one line to remember
You can buy it. That’s all this word means.
Selling it “for research” sidesteps the rules for human use — it doesn’t make that use allowed.
No agency has confirmed it does what’s claimed. Most evidence is early or from animal studies.
Nobody guarantees what’s in the vial, how pure it is, or how much.
A peptide can be the first and none of the rest. Gray-market means available — the other three are open questions.
What “for research only” actually does
Selling a compound as a “research chemical” — with a “not for human use” label — is what lets a vendor ship it without going through drug approval or compounding. The label is a legal position for the seller, not a statement about quality. Once it’s in your hands, there is no agency checking that the contents match the label.
The part that surprises people: it’s often not what the label says
Because nobody verifies gray-market vials, independent testing keeps finding contents that don’t match the label — wrong identity, wrong dose, or contaminants. In one widely-cited round of lab testing, a batch sold as one peptide turned out to be a different compound entirely.
Trade-lab reporting has described roughly 1 in 5 unapproved vials as mislabeled, including a sample marketed as retatrutide that tested as semaglutide.S2 Treat the exact figure as provisional — we’re pinning a primary lab source before stating it flat.
Why many peptides never leave the gray market
Getting to “approved” — or even onto the compounding list — takes someone willing to fund the work. For a lot of peptides, that never happens. Three common reasons:
Trials cost years and millions. If a compound can’t be patented into a profitable product, no company pays for that.
Much of what exists is animal or cell-model work. Without solid human safety data, a compound stalls before any pathway opens.
Some peptides were put forward for the compounding list and then pulled — landing in Category 2’s “nominated but withdrawn” and going no further.
The result: they stay available indefinitely without ever becoming legal, proven, or quality-controlled. “Still on the gray market” is often the permanent status, not a waiting room.
Sources
Primary and trade references behind this explainer. Figures marked provisional are being confirmed against primary lab data.
-
01
FDA — Certain Bulk Drug Substances for Use in Compounding (Category 2)fda.gov · Federal regulatory listing
-
02
RAPS — FDA considers adding a dozen peptides to its bulk drug compounding listraps.org · Trade / association reporting · figure pending primary confirmation